Navigation Links
Cell Therapeutics, Inc. Announces Exercise of Overallotment
Date:7/23/2009

filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying prospectus relating to the offering may be obtained by contacting Rodman & Renshaw, LLC at 1251 Avenue of the Americas, 20th Floor, New York, New York 10020, or by calling (212) 356-0549.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our shares of common stock or warrants. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect the actual future results of the Company and the trading price of securities of the Company. The risks and uncertainties include the risk that the investors might not exercise their warrants, the Company might not be able to continue to raise additional capital as needed to fund its operations, the Company's intentions regarding the use of proceeds, and other risk factors listed or described from time to time in the Company's filings with the SEC, including, without limitation, its most recent filings on Forms 10-K, 10-Q and 8-K. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:

    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
2. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
3. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
4. Nile Therapeutics, Inc. To Raise $3.4 Million in Private Placement
5. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
6. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
7. Prospect Therapeutics, Inc.s GCS-100 Inhibited Blood Vessel Formation in a Variety of Cancer Models
8. Cell Therapeutics, Inc. (CTI) to Present at 2009 BIO International Convention
9. Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors
10. Cell Therapeutics, Inc. (CTI) to Report 2009 First Quarter Financial Results on May 7
11. Oxygen Biotherapeutics, Inc. Signs Supply Agreement for Clinical-Grade Oxycyte for Clinical Trials and Future Needs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... ... July 27, 2015 , ... This is ... report provides a basic overview of the industry including definitions, classifications, applications and ... including development trends, competitive landscape analysis, and key regions development status. Development policies ...
(Date:7/27/2015)... 2015 Research presented at the 2015 AACC ... the studies that led to a fingerprick Ebola test ... disease to receive approval from the World Health Organization ... grip on West Africa by ... workers to isolate and treat these patients much faster ...
(Date:7/27/2015)... Junto Health, a company that helps major ... new technology solutions, today announced the launch of a ... in health care policy consulting. Working together with SPG, ... innovation process while, at the same time, they are ... health care finance and the delivery of health care ...
(Date:7/25/2015)... ... ... Technology leader Anton Paar offers the Abbemat T-Check ... of the measuring prism. This is required to achieve the most precise refractive ... requirements. It is likely that no refractometer manufacturers on the market can traceably ...
Breaking Biology Technology:2015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4It’s T-Time for Refractometers: On-site Temperature Check Now Available 2
... community development specialist, presented a hopeful outlook for Wisconsin ... Economic Development . Abstaining from morbid statistics and pessimistic ... in Wisconsin. , ,Wisconsin manufacturing suffered very little in ... cited that Wisconsin saw only a 9.1 percent drop ...
... to escape detection by the immune system may also ... new hosts, scientists at the University of Wisconsin-Madison announced ... discovery may help researchers design vaccines that exploit the ... to attack the virus where it's most vulnerable. The ...
... Tuesday Herbert Conrad as chairman of the board of directors, ... of directors. , , Conrad is ... Inc. He served as the chairman of the board of ... a co-founder of Reliant Pharmaceuticals in addition to serving on ...
Cached Biology Technology:Optimistic Outlook For Manufacturing 2Studies Offer New Insight into HIV Vaccine Development 2
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015 ... the leading developer of human interface solutions, ... technology, the industry,s first fully hardware encapsulated ... Match-in-Sensor secure authentication technology is literally off ... storage and biometric matching within the fingerprint ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Aware,s CaptureSuite(TM) family of software kits applies advanced image, processing ... ... high-quality fingerprints, BEDFORD, Mass., Oct. 1 Aware, ... today,announced the introduction of CaptureSuite, a family of software,development kits ...
... scientific research are living longer despite cellular defects, a ... body ages and how doctors could one day limit ... to a new University of Colorado at Boulder study. ... researchers manipulated the metabolic state of genetically engineered lab ...
... 7:30 p.m. , The New York Academy of Sciences, ... New York, NY 10007 The Malaria Research Institute ... and The New York Academy of Sciences present Progress ... to highlight the latest research developments in the fight ...
Cached Biology News:Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 2Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture 3CU-Boulder worm study sheds light on human aging, inherited diseases 2CU-Boulder worm study sheds light on human aging, inherited diseases 3Progress Against Malaria: Developments on the Horizon 2
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
... stimulating factors for assays of mouse hematopoietic ... fetal liver. Suitable for the growth ... when added to methylcellulose at a final ... Will also support growth of mouse ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
...
Biology Products: